Joel Beatty
Stock Analyst at Baird
(4.06)
# 398
Out of 4,825 analysts
188
Total ratings
38%
Success rate
15.62%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LRMR Larimar Therapeutics | Maintains: Outperform | $13 → $10 | $2.86 | +249.65% | 2 | Mar 25, 2025 | |
| MNMD Mind Medicine (MindMed) | Maintains: Outperform | $27 → $16 | $6.59 | +142.79% | 2 | Mar 7, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Outperform | $32 → $16 | $3.96 | +304.04% | 2 | Mar 7, 2025 | |
| ARGX argenx SE | Maintains: Neutral | $650 → $680 | $639.90 | +6.27% | 6 | Mar 4, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $117 → $73 | $38.53 | +89.46% | 2 | Mar 3, 2025 | |
| CPRX Catalyst Pharmaceuticals | Maintains: Outperform | $28 → $32 | $24.27 | +31.85% | 2 | Mar 3, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $132 → $160 | $112.24 | +42.55% | 4 | Mar 3, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $10 → $8 | $5.63 | +42.10% | 4 | Feb 27, 2025 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $31 | $16.11 | +92.43% | 1 | Jan 7, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $10 → $8 | $1.62 | +393.83% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $70 | $49.52 | +41.36% | 14 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $30.62 | +144.94% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $154 → $162 | $117.18 | +38.25% | 3 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $11 | $5.14 | +114.01% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $1.68 | +316.67% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $72 | $15.40 | +367.53% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $62.71 | +3.65% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $240 → $175 | $62.25 | +181.12% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $9 | $7.48 | +20.32% | 4 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $112 → $127 | $99.25 | +27.96% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $58 | $21.70 | +167.28% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $38 | $30.58 | +24.26% | 2 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $38.97 | +84.76% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $20 | $0.48 | +4,045.08% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $14.57 | +92.18% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.43 | +214.69% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $11.16 | +124.01% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $0.42 | +2,067.63% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $13.79 | +103.05% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $7.58 | +111.22% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $1.79 | -30.17% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.62 | +2,616.05% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $14.04 | +313.11% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $20.47 | +17.24% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $12.50 | +44.00% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $2.71 | +121.40% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $46 → $31 | $1.34 | +2,213.43% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $6.08 | +360.53% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $255.13 | -31.41% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $4.46 | +213.90% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $62.78 | +72.03% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $31.71 | +145.98% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $8.61 | +1,061.44% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $10.98 | +992.90% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $3.75 | +11,900.00% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $0.98 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $6.41 | +134.01% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $120 | $0.77 | +15,480.37% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $6.49 | +192.76% | 3 | Nov 10, 2017 | |
Larimar Therapeutics
Mar 25, 2025
Maintains: Outperform
Price Target: $13 → $10
Current: $2.86
Upside: +249.65%
Mind Medicine (MindMed)
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $6.59
Upside: +142.79%
Contineum Therapeutics
Mar 7, 2025
Maintains: Outperform
Price Target: $32 → $16
Current: $3.96
Upside: +304.04%
argenx SE
Mar 4, 2025
Maintains: Neutral
Price Target: $650 → $680
Current: $639.90
Upside: +6.27%
Praxis Precision Medicines
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $38.53
Upside: +89.46%
Catalyst Pharmaceuticals
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $24.27
Upside: +31.85%
Axsome Therapeutics
Mar 3, 2025
Maintains: Outperform
Price Target: $132 → $160
Current: $112.24
Upside: +42.55%
Cogent Biosciences
Feb 27, 2025
Maintains: Neutral
Price Target: $10 → $8
Current: $5.63
Upside: +42.10%
Denali Therapeutics
Jan 7, 2025
Initiates: Outperform
Price Target: $31
Current: $16.11
Upside: +92.43%
Editas Medicine
Dec 13, 2024
Maintains: Outperform
Price Target: $10 → $8
Current: $1.62
Upside: +393.83%
Dec 3, 2024
Maintains: Outperform
Price Target: $52 → $70
Current: $49.52
Upside: +41.36%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $30.62
Upside: +144.94%
Nov 18, 2024
Maintains: Outperform
Price Target: $154 → $162
Current: $117.18
Upside: +38.25%
Nov 18, 2024
Upgrades: Outperform
Price Target: $3 → $11
Current: $5.14
Upside: +114.01%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.68
Upside: +316.67%
Nov 12, 2024
Maintains: Outperform
Price Target: $54 → $72
Current: $15.40
Upside: +367.53%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $62.71
Upside: +3.65%
Oct 21, 2024
Maintains: Outperform
Price Target: $240 → $175
Current: $62.25
Upside: +181.12%
Oct 9, 2024
Maintains: Neutral
Price Target: $13 → $9
Current: $7.48
Upside: +20.32%
Aug 2, 2024
Maintains: Outperform
Price Target: $112 → $127
Current: $99.25
Upside: +27.96%
Jul 26, 2024
Initiates: Outperform
Price Target: $58
Current: $21.70
Upside: +167.28%
Jul 25, 2024
Maintains: Outperform
Price Target: $37 → $38
Current: $30.58
Upside: +24.26%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $38.97
Upside: +84.76%
May 15, 2024
Maintains: Outperform
Price Target: $45 → $20
Current: $0.48
Upside: +4,045.08%
May 9, 2024
Maintains: Outperform
Price Target: $31 → $28
Current: $14.57
Upside: +92.18%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.43
Upside: +214.69%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $11.16
Upside: +124.01%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $0.42
Upside: +2,067.63%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $13.79
Upside: +103.05%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $7.58
Upside: +111.22%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $1.79
Upside: -30.17%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.62
Upside: +2,616.05%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $14.04
Upside: +313.11%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $20.47
Upside: +17.24%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $12.50
Upside: +44.00%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $2.71
Upside: +121.40%
Jun 1, 2022
Maintains: Outperform
Price Target: $46 → $31
Current: $1.34
Upside: +2,213.43%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $6.08
Upside: +360.53%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $255.13
Upside: -31.41%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $4.46
Upside: +213.90%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $62.78
Upside: +72.03%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $31.71
Upside: +145.98%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $8.61
Upside: +1,061.44%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $10.98
Upside: +992.90%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $3.75
Upside: +11,900.00%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $0.98
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $6.41
Upside: +134.01%
Aug 17, 2018
Maintains: Neutral
Price Target: $240 → $120
Current: $0.77
Upside: +15,480.37%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $6.49
Upside: +192.76%